In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Mean cost of bringing new drug to US market Is $879.3 million
Jul 02, 2024
R&D has remained relatively stable among large pharma companies despite a 27.3% growth in sales.
Company hid problems with COVID-19 vaccines from FDA
May 10, 2022
Nearly 400 million doses of vaccine made by Emergent had to be destroyed “due to poor quality control.”
Effects of intranasal insulin on cognition, mobility studied in elderly
May 05, 2022
Evidence from a phase 2 trial suggests positive effects on cognition and gait in elderly patients with type 2 diabetes.
Sanofi follows Lilly, Novo Nordisk in cutting insulin prices
Mar 17, 2023
Sanofi is the third company to cut prices on its insulin products and cap out-of-pocket charges to $35 a month.
J&J vaccine guards against Delta variant, company says
Jul 02, 2021
Although there was a slight drop in potency against the Delta variant, the vaccine was more effective against the Delta variant than the Beta variant.
Elon Musk’s Neuralink says brain-to-computer interface has FDA approval for clinical trial
May 26, 2023
The device would be surgically implanted into patients’ brains, with the idea that it would connect with computers to decode brain activity.
Mindfulness training, exercise no aid for cognitive function
Dec 21, 2022
No benefit was seen for episodic memory or executive function at six or 18 months for older adults, but cognitive performance didn’t decline either.
New Sanofi-GSK COVID-19 vaccine highly effective, companies say
Feb 23, 2022
In laboratory studies, two doses of the vaccine stimulated the production of more neutralizing antibodies than an approved mRNA vaccine.
New COVID-19 drug guards against all variants in immunocompromised
Apr 28, 2023
The trial results could be out by September and may lead to the FDA emergency use authorization.